Juliette Brenner, Anna E M Bastiaansen, Mar Guasp, Sergio Muñiz-Castrillo, Takahiro Iizuka, Marienke A A M de Bruijn, Amaia Muñoz-Lopetegi, Eugenia Martínez-Hernández, Géraldine Picard, Alberto Vogrig, Mathilde Millot, Carsten Finke, Christian Geis, Jan Lewerenz, Nico Melzer, Harald Prüss, Saskia Räuber, Marius Ringelstein, Kevin Rostàsy, Kurt-Wolfram Sühs, Franziska S Thaler, Klaus-Peter Wandinger, Katharina Wurdack, Yvette S Crijnen, Jeroen Kerstens, Robin W van Steenhoven, Sharon Veenbergen, Marco W J Schreurs, Robert van den Berg, Victor Volovici, Rinze F Neuteboom, Juna M de Vries, Peter A E Sillevis Smitt, Mariska M P Nagtzaam, Suzanne C Franken; GENERATE Study Group; Josep Dalmau, Frank Leypoldt, Jérôme Honnorat, Maarten J Titulaer.
Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.
Lancet Reg Health Eur. 2025 Dec 11:62:101562. doi: 10.1016/j.lanepe.2025.101562. eCollection 2026 Mar. PubMed ID: 41488792
Further Information: